Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aprameya EngineeringNSE:APRAMEYA -0.94%41 Debt-to-EBITDA is -18.77 as of Mar. 2026. GuruFocus rates NSE:APRAMEYA with a GF Score™ of 41/100. The stock has 6 warning signs investors should review. Among 466 Medical Devices & Instruments companies, Aprameya Engineering ranks better than 66.52% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Aprameya Engineering's Debt-to-EBITDA or its related term are showing as below:
NSE:APRAMEYA'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.55 Med: 1.24 Max: 6.58
Current: 0.65
During the past 7 years, the highest Debt-to-EBITDA Ratio of Aprameya Engineering was 6.58. The lowest was 0.55. And the median was 1.24.
NSE:APRAMEYA's Debt-to-EBITDA is ranked better than 66.52% of 466
companies
in the Medical Devices & Instruments industry
Industry Median: 1.585
vs NSE:APRAMEYA: 0.65
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Aprameya Engineering Debt-to-EBITDA Related Terms
Aprameya Engineering Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Aprameya Engineering's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:APRAMEYA vs ISRG, BDX, MDLN: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Aprameya Engineering's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aprameya Engineering Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aprameya Engineering's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Aprameya Engineering's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Mar. 2026) EBITDA data.
Aprameya Engineering (NSE:APRAMEYA) has a Debt-to-EBITDA of -18.77 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Aprameya Engineering. Over the past decade, Aprameya Engineering's Debt-to-EBITDA has ranged from 0.55 to 6.58. According to the industry distribution chart, Aprameya Engineering ranks #156 out of 466 companies in the Medical Devices & Instruments industry, placing it in the top 33.5%.
Is Aprameya Engineering's Debt-to-EBITDA too high?
Aprameya Engineering's current Debt-to-EBITDA is -18.77. Over the past 10 years, this metric has ranged from a low of 0.55 to a high of 6.58. Based on the distribution chart, Aprameya Engineering ranks #156 out of 466 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Aprameya Engineering has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Aprameya Engineering's Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Aprameya Engineering ranks #156 out of 466 companies for Debt-to-EBITDA. This puts Aprameya Engineering in the upper half of its industry. The industry median Debt-to-EBITDA is 1.59. Historically, Aprameya Engineering's own Debt-to-EBITDA has ranged from 0.55 to 6.58 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.59, based on 466 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Aprameya Engineering. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aprameya Engineering's current Debt-to-EBITDA is -18.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprameya Engineering stock overvalued right now?
Aprameya Engineering (NSE:APRAMEYA) has a current Debt-to-EBITDA of -18.77. The current Debt-to-EBITDA is -18.77. Aprameya Engineering's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Aprameya Engineering (NSE:APRAMEYA), the current Debt-to-EBITDA is -18.77 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aprameya Engineering Ltd is engaged in the business of installation, set up & maintenance of Intensive Care Units (ICU), Neonatal Intensive Care Units (NICU), Pediatric Intensive Care Units (PICU), Operation Theatre, dialysis centres and prefabricated structure ward (hereinafter referred to as Healthcare Infrastructure projects) in the hospitals and medical care centers on turnkey basis with the supply of high-value healthcare equipment and diagnostic equipment to private hospitals, Government hospitals, and medical practitioners. The company has two Business segments: Trading of Medical support Equipment (Trading Sales) and Supplies for Infra Projects for health care sectors (Turnkey project supplies). Key revenue is generated from Trunkey Project Supply.
41GF Score
Get the complete analysis for NSE:APRAMEYA
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:APRAMEYA has been successfully added to your 
